eli lilly's tirzepatide is the leader in weight loss sector Novo Nordisk Says 'Gold Standard' GLP-1 Comparison Misleads Consumers Eli Lilly First to Launch

The classification of Rybelsus as a GLP-1 receptor agonist is reflected in its Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and available on the electronic medicines compendium (emc)

In addition to these, drug therapy, such as the use of GLP-1RA in medications for weight loss, has made significant progress

Though it contains the same active ingredient as Ozempic, its dosing protocol is tailored to appetite suppression and fat reduction

Retatrutide, in clinical trials, is administered via subcutaneous injection, typically once weekly, with doses ranging from 0.5 mg to 12 mg